Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (NCT06293898)
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- City of Hope — Duarte, California
- Cedars Sinai — Los Angeles, California
- Scripps Health — San Diego, California
- University of Miami — Miami, Florida
- Sarah Cannon Research institute - Lake Nona Florida — Orlando, Florida
- Georgia Cancer Center at Augusta University — Augusta, Georgia
- University of Illinois Cancer Center — Chicago, Illinois
- University of Chicago Medicine — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Institiute — Detroit, Michigan
- NYU Langone Hospital - Long Island Investigational Pharmacy — Mineola, New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Providence Portland Medical Center — Portland, Oregon
- Sarah Cannon Research Institute — Nashville, Tennessee
- Oncology Consultants — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (425) 453-6841
Email: christine.larock@systimmune.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Cancer
- Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer — Houston, Texas
- A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer — Little Rock, Arkansas
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
- Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa
Explore by condition: All Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.